Korean Registry of Percutaneous EVAR With INCRAFT Stent Graft for the Treatment of Abdominalaortic Aneurysm (K-INCRAFT)

NCT ID: NCT03952780

Last Updated: 2024-04-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

86 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-09-02

Study Completion Date

2023-09-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The sudy purpose is to investigate efficacy and safety of percutaneous endovascular aortic aneurysm repair using INCRAFT stent graft for Korean patients with abdominal aortic aneurysm. This study is designed as an investigator-initiated, multi-center, single-arm, prospective registry study. A total of 100 patients who meet all inclusion criteria, but none of exclusion criteria will be enrolled after the implantation of INCRAFT stent graft. The primary efficacy outcome is technical success defined as successful deployment of the stent-graft with no type I/III endoleak, unintentional coverage of visceral aortic branches or internal iliac arteries at the end of the procedure, and with successful removal of the delivery system. The primary safety outcome is major vascular complications at 30 days including. The study subjects will be followed for 12 months.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Prospective single-arm multicenter registry

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Abdominal Aortic Aneurysm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\. AAA with one of following indications

1. AAA with maximum diameter \> 5 cm,
2. AAA with maximum diameter \> 4 cm with an increase \>0.5 cm during the preceding 6 months
3. Saccular type AAA irrespective of the sac diameter.
* 2\. Proximal aortic neck length ≥10 mm with a diameter ≥ 17 and ≤ 31 mm in combination with supra- and infrarenal angulation ≤ 60 degree.
* 3\. Iliac landing zone with a length ≥15 mm and a diameter ≥ 7 and ≤ 22 mm
* 4\. Femoral access vessels should be adequate to fit the selected delivery system
* 5\. Minimum overall AAA treatment length (proximal landing location to distal landing location to distal landing location) ≥128 mm
* 6\. Aortic bifurcation \>18 mm in diameter
* 7\. Patents with age of 19-80 years.
* 8\. Male or non-pregnant female
* 9\. Voluntary participation in the study with signed informed consent form.

Exclusion Criteria

* 1\. Dissecting or ruptured abdominal aortic aneurysm
* 2\. Presence of connective tissue disease (Marfan's syndrome or Ehlers-Danlos syndrome).
* 3\. Prior AAA or iliac artery repair
* 4\. Active infection or active vasculitis.
* 5\. Myocardial infarction or cerebrovascular accident within 3 months prior to study enrolment.
* 6\. Need for renal artery coverage (e.g. Chimney graft)
* 7\. Dialysis-dependent renal failure or serum creatinine \>2.0 mg/dl
* 8\. Intolerance/hypersensitivity to contrast media or antiplatelet drugs.
* 9\. Positive pregnancy test.
* 10\. Participation in another medical research study within 1 month of study enrolment.
* 11\. Planned concomitant surgical procedures (other than left subclavian artery transposition or bypass) or major surgery within 30 days of study enrolment.
* 12\. Patients with life expectancy less than 1 year
Minimum Eligible Age

19 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Yonsei University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University Health System, 50 Yonsei-ro, Seodaemun-gu

Seoul, , South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1-2018-0081

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Chronic Total Occlusion Registry
NCT04041921 TERMINATED